Estimating the impact of mammography screening disruptions during the COVID-19 pandemic

估计 COVID-19 大流行期间乳房 X 光检查筛查中断的影响

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT Breast density is a risk factor for developing breast cancer and decreases the accuracy of screening mammography. An estimated 27 million women aged 40-74 in the U.S. have dense breasts and they experience elevated rates of advanced stage breast cancer diagnoses associated with poor outcomes. Thirty- seven states now require mammography facilities to notify women with dense breasts of the limitations of mammography and recommend discussion of screening options with their healthcare providers, and a national law is pending. In the absence of screening guidelines for women with dense breasts, there has been a dramatic increase in use of supplemental ultrasound screening, which is widely available and has low direct medical costs. Early studies of supplemental ultrasound performance suggest increased cancer detection but high rates of false positive exams leading to unnecessary biopsies. The United States Preventive Services Task Force has called for studies that evaluate the impact of supplemental ultrasound screening on meaningful clinical outcomes, such as advanced cancer rates, to inform screening guidelines for women with dense breasts. We recently demonstrated that mammography screening failure rates (i.e., advanced cancers and interval cancers after a normal mammogram) among women with dense breasts vary widely according to clinical risk factors. Therefore, we propose to assess supplemental ultrasound screening performance within a new risk-based framework. We hypothesize that supplemental ultrasound screening targeted to the subset of women with dense breasts at high risk of mammography screening failures will yield a favorable benefit-to- harm profile. We will use observational data from more than 100,000 screening ultrasound exams and 2 million mammography screening exams collected via the Breast Cancer Surveillance Consortium to (Aim 1) examine the test performance of supplemental screening ultrasound according to technique (handheld vs. automated) and type of primary screening (digital mammography vs. digital breast tomosynthesis); and (Aim 2) evaluate supplemental screening ultrasound outcomes across levels of risk for mammography screening failures. These results will be used as inputs in two simulation models from the Cancer Intervention and Surveillance Modeling Network to (Aim 3) evaluate the long-term benefits, harms, and costs of supplemental ultrasound strategies targeted to women at high risk of mammography screening failures. Our study will be the largest evaluation of supplemental ultrasound and the first to evaluate rates of interval and advanced cancers according to risk of mammography screening failures. Our results will provide urgently needed, actionable evidence for women, healthcare providers, and guideline-makers evaluating screening options for women with dense breasts. This evidence will support effective supplemental screening strategies that reduce the burden of breast cancer among women for whom mammography screening is not adequate, while minimizing potential harms.
项目摘要/摘要 乳房密度是患乳腺癌的危险因素,并降低了筛查的准确性 乳房X线摄影。美国估计有2700万妇女在美国有40-74岁的乳房,她们 与结果不佳有关的晚期乳腺癌诊断率升高。三十- 现在,七个州需要乳房X线摄影设施来通知乳房密集的妇女的局限性 乳房X线摄影并建议与他们的医疗保健提供者讨论筛查选项,以及一个国家 法律正在等待。在没有针对乳房密集的女性筛查指南的情况下,已经有一个 补充超声筛选的使用急剧增加,该筛选可广泛可用,直接较低 医疗费用。补充超声表现的早期研究表明癌症的检测增加了 高阳性考试的高率导致不必要的活检。美国预防服务 工作队呼吁进行研究,以评估补充超声筛选对有意义的影响 临床结果,例如晚期癌症,以告知筛查指南 乳房。我们最近证明了乳房X线摄影筛查衰竭率(即高级癌症和 正常乳房X线照片后的间隔癌)在乳房密集的女性中差异很大 临床风险因素。因此,我们建议评估在 基于风险的新框架。我们假设针对子集的补充超声筛选 具有乳房X线摄影筛查失败风险高的乳房的妇女将带来有利的收益。 危害概况。我们将使用超过100,000次筛选超声考试和200万次筛选的观察数据 通过乳腺癌监视联盟收集的乳房X线摄影检查检查(目标1)检查 根据技术(手持式与自动化)的补充筛查超声检查的测试性能 和主要筛查类型(数字乳房摄影与数字乳房间隔); (目标2)评估 跨乳房X线摄影筛查失败风险范围的补充筛查超声结果。这些 结果将用作癌症干预和监视模型的两个模拟模型中的输入 网络以(目标3)评估补充超声策略的长期收益,危害和成本 针对具有乳房X线摄影筛查失败风险的女性。我们的研究将是对 补充超声波和第一个根据风险评估间隔和高级癌症发生率的风险 乳房X线摄影筛查失败。我们的结果将为妇女提供急需的,可行的证据, 医疗保健提供者和指南制定者评估乳房密集的妇女的筛查选择。这 证据将支持有效的补充筛查策略,以减轻乳腺癌的负担 在乳房X线摄影筛查不足的女性中,同时最大程度地减少了潜在危害。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Brian L Sprague其他文献

Brian L Sprague的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Brian L Sprague', 18)}}的其他基金

Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis
高风险良性乳腺诊断女性的临床乳腺癌风险预测模型
  • 批准号:
    10719777
  • 财政年份:
    2023
  • 资助金额:
    $ 18万
  • 项目类别:
Identifying effective risk-based supplemental ultrasound screening strategies for women with dense breasts
为乳房致密的女性确定有效的基于风险的补充超声筛查策略
  • 批准号:
    10113566
  • 财政年份:
    2020
  • 资助金额:
    $ 18万
  • 项目类别:
Identifying effective risk-based supplemental ultrasound screening strategies for women with dense breasts
为乳房致密的女性确定有效的基于风险的补充超声筛查策略
  • 批准号:
    10359684
  • 财政年份:
    2020
  • 资助金额:
    $ 18万
  • 项目类别:
Identifying effective risk-based supplemental ultrasound screening strategies for women with dense breasts
为乳房致密的女性确定有效的基于风险的补充超声筛查策略
  • 批准号:
    10555224
  • 财政年份:
    2020
  • 资助金额:
    $ 18万
  • 项目类别:
Vermont Breast Cancer Molecular Characterization Laboratory
佛蒙特州乳腺癌分子表征实验室
  • 批准号:
    10253243
  • 财政年份:
    2015
  • 资助金额:
    $ 18万
  • 项目类别:
Vermont Breast Cancer Molecular Characterization Laboratory
佛蒙特州乳腺癌分子表征实验室
  • 批准号:
    9551743
  • 财政年份:
    2015
  • 资助金额:
    $ 18万
  • 项目类别:
Vermont Breast Cancer Molecular Characterization Laboratory
佛蒙特州乳腺癌分子表征实验室
  • 批准号:
    9142299
  • 财政年份:
    2015
  • 资助金额:
    $ 18万
  • 项目类别:
Vermont Breast Cancer Molecular Characterization Laboratory
佛蒙特州乳腺癌分子表征实验室
  • 批准号:
    8928679
  • 财政年份:
    2015
  • 资助金额:
    $ 18万
  • 项目类别:
Vermont Breast Cancer Molecular Characterization Laboratory
佛蒙特州乳腺癌分子表征实验室
  • 批准号:
    9334814
  • 财政年份:
    2015
  • 资助金额:
    $ 18万
  • 项目类别:
Vermont Administrative Core
佛蒙特州行政核心
  • 批准号:
    8715713
  • 财政年份:
    2014
  • 资助金额:
    $ 18万
  • 项目类别:

相似海外基金

Planning and Evaluation Core
规划与评估核心
  • 批准号:
    10762147
  • 财政年份:
    2023
  • 资助金额:
    $ 18万
  • 项目类别:
BCM-TSU CURED Administration Core (AC)
BCM-TSU CURED 管理核心 (AC)
  • 批准号:
    10762266
  • 财政年份:
    2023
  • 资助金额:
    $ 18万
  • 项目类别:
BCM/TSU P20 Collaborative Union for Cancer Research, Education and Disparities (CURED) Administrative Core (AC)
BCM/TSU P20 癌症研究、教育和差异合作联盟 (CURED) 行政核心 (AC)
  • 批准号:
    10762046
  • 财政年份:
    2023
  • 资助金额:
    $ 18万
  • 项目类别:
Planning and Evaluation Core
规划与评估核心
  • 批准号:
    10762276
  • 财政年份:
    2023
  • 资助金额:
    $ 18万
  • 项目类别:
Therapeutic targeting of RTK protein granules in cancer
RTK 蛋白颗粒在癌症中的治疗靶向
  • 批准号:
    10591331
  • 财政年份:
    2023
  • 资助金额:
    $ 18万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了